DCTH vs. NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, CDRE, AORT, and LQDA
Should you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), Cadre (CDRE), Artivion (AORT), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry.
Delcath Systems vs. Its Competitors
Delcath Systems (NASDAQ:DCTH) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.
Delcath Systems has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.
In the previous week, NovoCure had 9 more articles in the media than Delcath Systems. MarketBeat recorded 10 mentions for NovoCure and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.89 beat NovoCure's score of 0.52 indicating that Delcath Systems is being referred to more favorably in the media.
Delcath Systems has a net margin of -26.38% compared to NovoCure's net margin of -26.41%. Delcath Systems' return on equity of -29.44% beat NovoCure's return on equity.
Delcath Systems has higher earnings, but lower revenue than NovoCure. Delcath Systems is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.
Delcath Systems presently has a consensus target price of $24.00, indicating a potential upside of 91.85%. NovoCure has a consensus target price of $32.83, indicating a potential upside of 83.63%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than NovoCure.
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 17.4% of Delcath Systems shares are owned by insiders. Comparatively, 5.5% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Delcath Systems beats NovoCure on 10 of the 14 factors compared between the two stocks.
Get Delcath Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Delcath Systems Competitors List
Related Companies and Tools
This page (NASDAQ:DCTH) was last updated on 7/2/2025 by MarketBeat.com Staff
Free DCTH Stock Alerts